Page 3 - Ongoing Phase News Today

Montrouge, France, November 9, 2023DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPE...

Initial evidence of dose-dependent disease control rate with 50% disease control rate at higher doses and 31% disease control rate across all dose levels in a range of solid tumor types, including...

– ABP-450 doses of 150 units and 195 units showed treatment effect of 4.8 days and 5.0 days, respectively, in the mean change from baseline in monthly...

Achieved significant enrollment milestones in three ongoing Phase 2 clinical trialsBroadened patent protection for proprietary -endoxifenStrengthened management team with appointment of Greg Weaver as... -Today at 08:32 am- MarketScreener

BUSINESS SECTION Overview Company Overview We are a clinical-stage biopharmaceutical company focused on developing...

Regulatory progress for govorestat for the treatment of Classic Galactosemia, with potential NDA submission based on discussions with the FDA as well as EMA Marketing Authorization Application... -Today at 07:04 am- MarketScreener

Positive Review from the Drug Safety Monitoring Board (DSMB) on the Ongoing Phase 2 Clinical Trial in Ulcerative Colitis. Positive Opinion for Orphan Drug Designation from the European Medicines Agency in the

Ongoing Phase IIb study expands to arm B5-year results of phase I study confirm efficacy and safety of novel immune-tolerance inducing cell therapy in organ transplantationSecond closing of Series A

Brii Biosciences has acquired worldwide exclusive license to VBI-2601 and an exclusive license for PreHevbri® in the Asia Pacific region VBI will receive gross proceeds of $15 million in upfront payments, subject to near-term milestone achievements, including an equity investment of approximately $3 million VBI is eligible to receive up to $422 million in additional potential regulatory and commercial milestone payments, plus double-digit royalties

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 5, 2023--